SWKH · CIK 1089907
What SWK Holdings Corp. told the SEC could break it.
Concentration runs through nearly everything SWK disclosed. Its MOD3 pharmaceutical-development business drew about 97.5% of its revenue from a single customer in 2025, and that contract-manufacturing operation depends on third-party raw materials that are sometimes single-sourced — at times from the specific supplier the customer designates — with no long-term supply contracts. Ownership is just as concentrated: Carlson-affiliated funds hold 75.1% of the stock and control board and major decisions, and SWK is in a pending merger after which it will no longer operate as an independent platform. It also flagged FDA regulation of both the life-sciences products underlying its royalty streams and its MOD3 facility's manufacturing compliance.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- MOD3 one customer = ~97.5% of pharma-dev revenue; Finance Receivables three customers = 33.9%high
SWK has severe customer concentration — its MOD3 pharmaceutical-development segment derived ~97.5% of revenue from a single customer (96% in 2024), and its Finance Receivables segment had three customers at 33.9% of revenue and four partners at 48.3% of interest/accounts receivable.
“For the year ended December 31, 2025 and 2024, the Company had one customer that accounted for approximately 97.5 % and 96.0 % of pharmaceutical development revenues, respectively.”
SEC filing →As of 2026
Other disclosures
- Carlson controls 75.1% of common stock; pending merger to cease independent operationhigh
Funds affiliated with Carlson own ~75.1% of SWK's common stock and (via a Stockholders' Agreement) control director elections, management and major transactions with potential conflicting objectives; SWK is also subject to a pending merger after which it will cease operating as an independent platform.
“As of December 31, 2025, Carlson owned in the aggregate 75.1% of our combined issued and outstanding commo”
SEC filing →As of 2026
Sole-source dependency
- MOD3 single-source raw-material suppliers (no long-term contracts; customers specify suppliers)high
SWK's MOD3 CDMO relies on third parties for most raw materials/supplies — in some cases only a single source or limited quantities, sometimes the specific supplier the customer designates — with no long-term supply contracts, so a supplier failure or CGMP non-compliance could delay or cancel manufacturing runs.
“In certain instances, the raw materials and other items can only be supplied by a limited number of suppliers and, in some cases, a single source, or in limited quantities. If third-party suppliers do not supply raw materials or other items on a timely basis, it may cause a manufacturing run to be delayed or canceled which would adversely impact our financial condition and results of operations. Additionally, we do not have long”
SEC filing →As of 2026
Regulatory & policy
- FDA/life-sciences regulation of products underlying its royalties and MOD3 CGMP compliancemedium
SWK invests in cash-flow streams from life-sciences products subject to extensive FDA (and foreign) regulation, and its MOD3 facility is subject to FDA CGMP inspection — non-compliance by SWK's products/partners or MOD3 could trigger penalties, suspend production, and impair royalty/interest collections.
“We have invested and plan to continue investing in cash flow streams produced by life sciences products that are subject to extensive regulation by the U.S. Food and Drug Administration”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch